Loading...

BCRX BIOCRYST PHARMACEUTICALS INC US FDA Inspections 8-K Filing

BCRY

BCRX

BIOCRYST PHARMACEUTICALS INC

(BCRX)

2025 8-K

Show Summary

Show Summary

Stock Purchase Agreement

Clinical Trials

New Product Launches

Financial Statements

Management Changes

CFO Resignation

Financial Results

Investor Conference

Q3 Financial Results

Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval

Financial Results Announcement

Financial Results Announcement

By-Laws Amendment

Financial Results

Departure of Directors

Commercialization Agreement...

Regulation FD Disclosure

License Agreement for Avora...

Financial Results Announcement

Clinical Trial Enrollment

Financial Results and Busin...

Annual Meeting Approval of ...

Financial Results and Busin...

External Links:

On June 23, 2025, the FDA extended the review date for BioCryst Pharmaceuticals' new drug application for ORLADEYO for pediatric patients with hereditary angioedema, moving the goal date to December 12, 2025 due to additional submission requirements.

AI Assistant

BIOCRYST PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.